Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:EWTXNASDAQ:SDGRNASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.29+2.0%$1.38$1.01▼$3.45$364.03M1.091.73 million shs147,698 shsEWTXEdgewise Therapeutics$13.27+1.6%$14.77$10.60▼$38.12$1.39B0.281.21 million shs280,105 shsSDGRSchrodinger$20.83+1.7%$23.30$16.60▼$28.47$1.53B1.631.14 million shs235,687 shsSPRYARS Pharmaceuticals$18.83+4.1%$14.56$7.89▼$18.89$1.85B0.841.32 million shs1.21 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca-8.70%-10.00%+16.67%-17.11%-42.73%EWTXEdgewise Therapeutics-8.86%-9.74%-8.80%-43.88%-25.29%SDGRSchrodinger-0.34%-2.66%-4.70%+2.66%+9.87%SPRYARS Pharmaceuticals+4.75%+13.64%+23.67%+44.76%+123.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca2.8461 of 5 stars3.50.00.00.03.82.51.3EWTXEdgewise Therapeutics2.7191 of 5 stars4.41.00.00.01.43.30.0SDGRSchrodinger2.45 of 5 stars3.51.00.00.02.72.50.6SPRYARS Pharmaceuticals3.2816 of 5 stars3.62.00.00.02.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57255.75% UpsideEWTXEdgewise Therapeutics 2.78Moderate Buy$39.78199.78% UpsideSDGRSchrodinger 3.00Buy$32.8057.47% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0064.64% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, SPRY, EWTX, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$48.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/16/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/3/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.004/2/2025EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.004/2/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/ASDGRSchrodinger$207.54M7.36N/AN/A$5.78 per share3.60SPRYARS Pharmaceuticals$89.15M20.74$0.01 per share2,038.19$2.64 per share7.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)Latest ERAS, SPRY, EWTX, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35EWTXEdgewise TherapeuticsN/A20.9920.99SDGRSchrodingerN/A3.453.45SPRYARS Pharmaceuticals0.3011.0010.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%EWTXEdgewise TherapeuticsN/ASDGRSchrodinger79.05%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%EWTXEdgewise Therapeutics23.20%SDGRSchrodinger8.60%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionableEWTXEdgewise Therapeutics60105.20 million80.79 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableERAS, SPRY, EWTX, and SDGR HeadlinesRecent News About These CompaniesLeerink Partnrs Analysts Raise Earnings Estimates for SPRYJune 26 at 2:18 AM | americanbankingnews.comQ2 EPS Estimate for ARS Pharmaceuticals Boosted by AnalystJune 25 at 6:12 AM | marketbeat.comHarbour Capital Advisors LLC Purchases New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 25 at 5:27 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLCJune 25 at 5:02 AM | marketbeat.comWhat is Leerink Partnrs' Estimate for SPRY FY2029 Earnings?June 25 at 2:54 AM | americanbankingnews.comBrokers Offer Predictions for SPRY FY2029 EarningsJune 24 at 6:39 AM | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $240,000.00 in StockJune 23, 2025 | americanbankingnews.comJanney Montgomery Scott LLC Boosts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 23, 2025 | marketbeat.comEric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockJune 20, 2025 | marketbeat.com249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource CouncilJune 20, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Average Target Price from BrokeragesJune 19, 2025 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comJim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”June 15, 2025 | msn.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 4.9% - Still a Buy?June 13, 2025 | marketbeat.comCantor Fitzgerald Estimates SPRY FY2026 EarningsJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Sells 115,987 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 6, 2025 | marketbeat.comBank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 5, 2025 | marketbeat.comAmeriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)June 3, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3% - Here's WhyMay 31, 2025 | marketbeat.comARS Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 50,000 SharesMay 23, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, SPRY, EWTX, and SDGR Company DescriptionsErasca NASDAQ:ERAS$1.28 +0.03 (+1.98%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Edgewise Therapeutics NASDAQ:EWTX$13.27 +0.21 (+1.60%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Schrodinger NASDAQ:SDGR$20.83 +0.34 (+1.65%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.ARS Pharmaceuticals NASDAQ:SPRY$18.83 +0.75 (+4.14%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
